NSCLC用標的薬剤ROS1阻害剤の世界市場:企業別、地域別、種類別、用途別、市場予測(~2024)

GlobalInfoResearchが発行した調査報告書(GIR9075842)
◆英語タイトル:Global Targeted Drug ROS1 Inhibitors for NSCLC Market 2019 by Company, Regions, Type and Application, Forecast to 2024
◆商品コード:GIR9075842
◆発行会社(リサーチ会社):GlobalInfoResearch
◆発行日:2019年6月(※2024年版があります。お問い合わせください。)
◆ページ数:122
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:医薬品・ヘルスケア
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD3,480 ⇒換算¥515,040見積依頼/購入/質問フォーム
Multi User(10名様閲覧用)USD5,220 ⇒換算¥772,560見積依頼/購入/質問フォーム
Corporate User(同一法人内共有可)USD6,960 ⇒換算¥1,030,080見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalInfoResearch社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalInfoResearch社の概要及び新刊レポートはこちらでご確認いただけます。

本調査レポートは、NSCLC用標的薬剤ROS1阻害剤の世界市場について調べ、まとめました。種類別セグメントは、クリゾチニブ、ロラチニブ、エントレクチニブ、その他等、用途別セグメントは、等に区分しました。NSCLC用標的薬剤ROS1阻害剤の世界市場概観、企業動向、企業別NSCLC用標的薬剤ROS1阻害剤シェア、市場規模推移、市場規模予測(2019年-2024年)、主要地域分析(北米、ヨーロッパ、アジア等)、主要国分析(日本、中国、アメリカ等)データなどの情報が含まれています。
・NSCLC用標的薬剤ROS1阻害剤の市場概観
・NSCLC用標的薬剤ROS1阻害剤の企業概要(事業概要、製品種類、販売量、価格、売上、市場シェア等)
・NSCLC用標的薬剤ROS1阻害剤の企業別販売動向、市場シェア、市場集中度、競争動向
・NSCLC用標的薬剤ROS1阻害剤の世界市場規模
・NSCLC用標的薬剤ROS1阻害剤の北米市場分析(アメリカ、カナダ、メキシコ等)
・NSCLC用標的薬剤ROS1阻害剤のアメリカ市場規模推移
・NSCLC用標的薬剤ROS1阻害剤のカナダ市場規模推移
・NSCLC用標的薬剤ROS1阻害剤のメキシコ市場規模推移
・NSCLC用標的薬剤ROS1阻害剤のヨーロッパ市場分析(ドイツ、イギリス、ロシア、フランス、イタリア等)
・NSCLC用標的薬剤ROS1阻害剤のドイツ市場規模推移
・NSCLC用標的薬剤ROS1阻害剤のイギリス市場規模推移
・NSCLC用標的薬剤ROS1阻害剤のロシア市場規模推移
・NSCLC用標的薬剤ROS1阻害剤のアジア太平洋市場分析(日本、中国、韓国、インド、東南アジア等)
・NSCLC用標的薬剤ROS1阻害剤の日本市場規模推移
・NSCLC用標的薬剤ROS1阻害剤の中国市場規模推移
・NSCLC用標的薬剤ROS1阻害剤の韓国市場規模推移
・NSCLC用標的薬剤ROS1阻害剤のインド市場規模推移
・NSCLC用標的薬剤ROS1阻害剤の東南アジア市場規模推移
・NSCLC用標的薬剤ROS1阻害剤の南米市場分析(ブラジル、アルゼンチン等)
・NSCLC用標的薬剤ROS1阻害剤の中東・アフリカ市場分析(サウジアラビア、UAE、南アフリカ等)
・NSCLC用標的薬剤ROS1阻害剤の種類別分析/販売量、売上、市場シェア(クリゾチニブ、ロラチニブ、エントレクチニブ、その他)
・NSCLC用標的薬剤ROS1阻害剤の用途別分析/市場規模()
・NSCLC用標的薬剤ROS1阻害剤の市場予測2019年-2024年(地域別予測、種類別予測、用途別予測)
・NSCLC用標的薬剤ROS1阻害剤の販売チャネル・代理店・貿易業者・ディーラー分析
【レポートの概要】

Scope of the Report:
The global Targeted Drug ROS1 Inhibitors for NSCLC market is valued at xx million USD in 2018 and is expected to reach xx million USD by the end of 2024, growing at a CAGR of xx% between 2019 and 2024.
The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.
North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of Targeted Drug ROS1 Inhibitors for NSCLC.
Europe also play important roles in global market, with market size of xx million USD in 2019 and will be xx million USD in 2024, with a CAGR of xx%.
This report studies the Targeted Drug ROS1 Inhibitors for NSCLC market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Targeted Drug ROS1 Inhibitors for NSCLC market by product type and applications/end industries.

Market Segment by Companies, this report covers
Roche
Pfizer
Beacon Pharma Limited
Drug International Limted
Incepta Pharmaceuticals

Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Market Segment by Type, covers
Crizotinib
Lorlatinib
Entrectinib
Other

Market Segment by Applications, can be divided into
Squamous Cell Carcinoma of NSCLC
Adenocarcinoma of NSCLC
Large Cell Carcinoma of NSCLC

【レポートの目次】

Table of Contents

1 Targeted Drug ROS1 Inhibitors for NSCLC Market Overview
1.1 Product Overview and Scope of Targeted Drug ROS1 Inhibitors for NSCLC
1.2 Classification of Targeted Drug ROS1 Inhibitors for NSCLC by Types
1.2.1 Global Targeted Drug ROS1 Inhibitors for NSCLC Revenue Comparison by Types (2019-2024)
1.2.2 Global Targeted Drug ROS1 Inhibitors for NSCLC Revenue Market Share by Types in 2018
1.2.3 Crizotinib
1.2.4 Lorlatinib
1.2.5 Entrectinib
1.2.6 Other
1.3 Global Targeted Drug ROS1 Inhibitors for NSCLC Market by Application
1.3.1 Global Targeted Drug ROS1 Inhibitors for NSCLC Market Size and Market Share Comparison by Applications (2014-2024)
1.3.2 Squamous Cell Carcinoma of NSCLC
1.3.3 Adenocarcinoma of NSCLC
1.3.4 Large Cell Carcinoma of NSCLC
1.4 Global Targeted Drug ROS1 Inhibitors for NSCLC Market by Regions
1.4.1 Global Targeted Drug ROS1 Inhibitors for NSCLC Market Size (Million USD) Comparison by Regions (2014-2024)
1.4.1 North America (USA, Canada and Mexico) Targeted Drug ROS1 Inhibitors for NSCLC Status and Prospect (2014-2024)
1.4.2 Europe (Germany, France, UK, Russia and Italy) Targeted Drug ROS1 Inhibitors for NSCLC Status and Prospect (2014-2024)
1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Targeted Drug ROS1 Inhibitors for NSCLC Status and Prospect (2014-2024)
1.4.4 South America (Brazil, Argentina, Colombia) Targeted Drug ROS1 Inhibitors for NSCLC Status and Prospect (2014-2024)
1.4.5 Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Targeted Drug ROS1 Inhibitors for NSCLC Status and Prospect (2014-2024)
1.5 Global Market Size of Targeted Drug ROS1 Inhibitors for NSCLC (2014-2024)
2 Manufacturers Profiles
2.1 Roche
2.1.1 Business Overview
2.1.2 Targeted Drug ROS1 Inhibitors for NSCLC Type and Applications
2.1.2.1 Product A
2.1.2.2 Product B
2.1.3 Roche Targeted Drug ROS1 Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2017-2018)
2.2 Pfizer
2.2.1 Business Overview
2.2.2 Targeted Drug ROS1 Inhibitors for NSCLC Type and Applications
2.2.2.1 Product A
2.2.2.2 Product B
2.2.3 Pfizer Targeted Drug ROS1 Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2017-2018)
2.3 Beacon Pharma Limited
2.3.1 Business Overview
2.3.2 Targeted Drug ROS1 Inhibitors for NSCLC Type and Applications
2.3.2.1 Product A
2.3.2.2 Product B
2.3.3 Beacon Pharma Limited Targeted Drug ROS1 Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2017-2018)
2.4 Drug International Limted
2.4.1 Business Overview
2.4.2 Targeted Drug ROS1 Inhibitors for NSCLC Type and Applications
2.4.2.1 Product A
2.4.2.2 Product B
2.4.3 Drug International Limted Targeted Drug ROS1 Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2017-2018)
2.5 Incepta Pharmaceuticals
2.5.1 Business Overview
2.5.2 Targeted Drug ROS1 Inhibitors for NSCLC Type and Applications
2.5.2.1 Product A
2.5.2.2 Product B
2.5.3 Incepta Pharmaceuticals Targeted Drug ROS1 Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2017-2018)
3 Global Targeted Drug ROS1 Inhibitors for NSCLC Market Competition, by Players
3.1 Global Targeted Drug ROS1 Inhibitors for NSCLC Revenue and Share by Players (2014-2019)
3.2 Market Concentration Rate
3.2.1 Top 5 Targeted Drug ROS1 Inhibitors for NSCLC Players Market Share
3.2.2 Top 10 Targeted Drug ROS1 Inhibitors for NSCLC Players Market Share
3.3 Market Competition Trend
4 Global Targeted Drug ROS1 Inhibitors for NSCLC Market Size by Regions
4.1 Global Targeted Drug ROS1 Inhibitors for NSCLC Revenue and Market Share by Regions
4.2 North America Targeted Drug ROS1 Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)
4.3 Europe Targeted Drug ROS1 Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)
4.4 Asia-Pacific Targeted Drug ROS1 Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)
4.5 South America Targeted Drug ROS1 Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)
4.6 Middle East and Africa Targeted Drug ROS1 Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)
5 North America Targeted Drug ROS1 Inhibitors for NSCLC Revenue by Countries
5.1 North America Targeted Drug ROS1 Inhibitors for NSCLC Revenue by Countries (2014-2019)
5.2 USA Targeted Drug ROS1 Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)
5.3 Canada Targeted Drug ROS1 Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)
5.4 Mexico Targeted Drug ROS1 Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)
6 Europe Targeted Drug ROS1 Inhibitors for NSCLC Revenue by Countries
6.1 Europe Targeted Drug ROS1 Inhibitors for NSCLC Revenue by Countries (2014-2019)
6.2 Germany Targeted Drug ROS1 Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)
6.3 UK Targeted Drug ROS1 Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)
6.4 France Targeted Drug ROS1 Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)
6.5 Russia Targeted Drug ROS1 Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)
6.6 Italy Targeted Drug ROS1 Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)
7 Asia-Pacific Targeted Drug ROS1 Inhibitors for NSCLC Revenue by Countries
7.1 Asia-Pacific Targeted Drug ROS1 Inhibitors for NSCLC Revenue by Countries (2014-2019)
7.2 China Targeted Drug ROS1 Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)
7.3 Japan Targeted Drug ROS1 Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)
7.4 Korea Targeted Drug ROS1 Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)
7.5 India Targeted Drug ROS1 Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)
7.6 Southeast Asia Targeted Drug ROS1 Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)
8 South America Targeted Drug ROS1 Inhibitors for NSCLC Revenue by Countries
8.1 South America Targeted Drug ROS1 Inhibitors for NSCLC Revenue by Countries (2014-2019)
8.2 Brazil Targeted Drug ROS1 Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)
8.3 Argentina Targeted Drug ROS1 Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)
8.4 Colombia Targeted Drug ROS1 Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)
9 Middle East and Africa Revenue Targeted Drug ROS1 Inhibitors for NSCLC by Countries
9.1 Middle East and Africa Targeted Drug ROS1 Inhibitors for NSCLC Revenue by Countries (2014-2019)
9.2 Saudi Arabia Targeted Drug ROS1 Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)
9.3 UAE Targeted Drug ROS1 Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)
9.4 Egypt Targeted Drug ROS1 Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)
9.5 Nigeria Targeted Drug ROS1 Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)
9.6 South Africa Targeted Drug ROS1 Inhibitors for NSCLC Revenue and Growth Rate (2014-2019)
10 Global Targeted Drug ROS1 Inhibitors for NSCLC Market Segment by Type
10.1 Global Targeted Drug ROS1 Inhibitors for NSCLC Revenue and Market Share by Type (2014-2019)
10.2 Global Targeted Drug ROS1 Inhibitors for NSCLC Market Forecast by Type (2019-2024)
10.3 Crizotinib Revenue Growth Rate (2014-2024)
10.4 Lorlatinib Revenue Growth Rate (2014-2024)
10.5 Entrectinib Revenue Growth Rate (2014-2024)
10.6 Other Revenue Growth Rate (2014-2024)
11 Global Targeted Drug ROS1 Inhibitors for NSCLC Market Segment by Application
11.1 Global Targeted Drug ROS1 Inhibitors for NSCLC Revenue Market Share by Application (2014-2019)
11.2 Targeted Drug ROS1 Inhibitors for NSCLC Market Forecast by Application (2019-2024)
11.3 Squamous Cell Carcinoma of NSCLC Revenue Growth (2014-2019)
11.4 Adenocarcinoma of NSCLC Revenue Growth (2014-2019)
11.5 Large Cell Carcinoma of NSCLC Revenue Growth (2014-2019)
12 Global Targeted Drug ROS1 Inhibitors for NSCLC Market Size Forecast (2019-2024)
12.1 Global Targeted Drug ROS1 Inhibitors for NSCLC Market Size Forecast (2019-2024)
12.2 Global Targeted Drug ROS1 Inhibitors for NSCLC Market Forecast by Regions (2019-2024)
12.3 North America Targeted Drug ROS1 Inhibitors for NSCLC Revenue Market Forecast (2019-2024)
12.4 Europe Targeted Drug ROS1 Inhibitors for NSCLC Revenue Market Forecast (2019-2024)
12.5 Asia-Pacific Targeted Drug ROS1 Inhibitors for NSCLC Revenue Market Forecast (2019-2024)
12.6 South America Targeted Drug ROS1 Inhibitors for NSCLC Revenue Market Forecast (2019-2024)
12.7 Middle East and Africa Targeted Drug ROS1 Inhibitors for NSCLC Revenue Market Forecast (2019-2024)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source

...

【免責事項】
https://www.globalresearch.jp/disclaimer

★リサーチレポート[ NSCLC用標的薬剤ROS1阻害剤の世界市場:企業別、地域別、種類別、用途別、市場予測(~2024)(Global Targeted Drug ROS1 Inhibitors for NSCLC Market 2019 by Company, Regions, Type and Application, Forecast to 2024)]についてメールでお問い合わせはこちらでお願いします。